With the delivery and administration of Covid-19 booster shots in full swing, it’s worth examining what lessons have been learned from the initial vaccine distribution—and if the supply chain is adapting accordingly to ensure a continued efficient rollout.
There is a saying that change is the only constant – therefore, to stay relevant, innovation needs to remain at the forefront of all business activity. Never has this been more important now, as we look towards the dawn of Industry 4.0.
The first industrial revolution saw mechanization through water and steam power, the second saw mass production and assembly lines using electricity, the third adopted computers and automation, and the fourth is set to build on this further, with smart and autonomous systems fuelled by data and machine learning.
Alf Goebel looks at what the pharmaceutical sector needs to do to ensure it is fit for digital purpose and takes its place at the top of the digital maturity rankings rather than hiding away at the bottom.
For a sector that provides the medicines needed to keep people healthy, figures such as these which show the sector is actively harming the planet are shocking. However, we must remember that climate change is a threat to the future of humanity, with carbon dioxide emissions being the biggest contributor to a warming planet.
The global COVID pandemic has been one of the worst disasters we have collectively faced for generations, resulting in hundreds of thousands of deaths, disabilities, and losses of livelihoods.
In a major step forward in the ongoing battle against fake goods – some of which include counterfeit medicines that harm thousands of consumers each year – two of the world’s leading companies specialized in the fields of serialization and track-and-trace have joined together in a strategic partnership: advanco and INEXTO.
The ongoing Covid-19 pandemic has shone a spotlight on the vulnerability of the world in the face of a serious pandemic. On a human front, it has caused hundreds of thousands of deaths and has left people with life-changing disabilities and ongoing health problems. On an economic front, it has cost the globe multiple billions of dollars and has left people jobless and struggling to make ends meet.
The pharmaceutical industry has battled the presence of counterfeit products for some time now. It is estimated that some 10 per cent of pharma products worldwide are counterfeit, resulting in up to 1 million deaths per year.
Regulatory compliance for serialisation is increasingly becoming a focus area for pharmaceutical manufacturers and supply chain partners across the world. Therefore, as would be expected, advanco is already well-known and solidly established within the pharmaceutical sector.
Despite significant challenges caused by COVID-19 disruptions, the pharmaceutical track-and-trace sector has made strides in three areas to help secure the global supply chain now and well into the future.
The ongoing problem of counterfeit drugs has been brought to mainstream attention following the seizure of 3,000 saline-filled vials being sold as Covid-19 vaccines in China at the beginning of February 2021.
Pharmaceutical counterfeiting brought to the fore, as more than 3,000 saline filled vials being sold as COVID-19 vaccines were seized in Chinese police raids.
A strategic serialization partnership has been announced by advanco and Syntegon, aimed at tackling the global issue of counterfeit drugs.
Advanco and Syntegon have announced a strategic partnership, marking a significant step towards helping to eradicate the growing problem of counterfeit drugs. The counterfeit drug market is estimated to exceed $75Bn and is once again in the spotlight as the world searches for a COVID-19 vaccine.
Demand from governments and health organisations for greater assurances on the integrity and reliability of pharmaceutical and medical products to treat COVID-19 has prompted advanco, a leader in product serialization tracking software, to accelerate its plans for growth across global markets.
EPM speaks to Rami Cassis, executive chairman of pharmaceutical serialisation company Advanco and CEO of Parabellum Investments about the rise in counterfeit medicines during the Covid-19 pandemic.